Oystein Bruserud

Summary

Affiliation: Haukeland University Hospital
Country: Norway

Publications

  1. doi request reprint The chemokine system in experimental and clinical hematology
    Øystein Bruserud
    Section for Hematology, Institute of Internal Medicine, University of Bergen, Bergen, Norway
    Curr Top Microbiol Immunol 341:3-12. 2010
  2. ncbi request reprint Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies
    Oystein Bruserud
    Section for Hematology, Institute of Clinical Science, University of Bergen, Bergen, Norway
    Cancer Immunol Immunother 63:757-77. 2014
  3. pmc Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience
    Knut Liseth
    Department of Immunology and Transfusion Medicine, Haukeland University Hospital, Bergen, Norway
    J Biomed Biotechnol 2010:692097. 2010
  4. ncbi request reprint Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML
    Øystein Bruserud
    Division for Hematology, Department of Medicine, Haukeland University Hospital, N 5021 Bergen, Norway
    Expert Opin Ther Targets 10:51-68. 2006
  5. ncbi request reprint In vitro culture of human acute lymphoblastic leukemia (ALL) cells in serum-free media; a comparison of native ALL blasts, ALL cell lines and virus-transformed B cell lines
    Øystein Bruserud
    Medical Department, Division of Hematology, Institute of Medicine, Haukeland University Hospital, N 5021 Bergen, Norway
    Leuk Res 27:455-64. 2003
  6. ncbi request reprint Human acute lymphoblastic leukemia (ALL) blasts as accessory cells during T-cell activation: differences between patients in costimulatory capacity affect proliferative responsiveness and cytokine release by activated T cells
    Oystein Bruserud
    Division of Hematology, Department of Medicine, Haukeland University Hospital, N 5021, Bergen, Norway
    Cancer Immunol Immunother 52:215-25. 2003
  7. ncbi request reprint Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities
    Øystein Bruserud
    Department of Medicine, Haukeland University Hospital, N 5021 Bergen, Norway
    Haematologica 88:416-28. 2003
  8. ncbi request reprint Effects of angiogenic regulators on in vitro proliferation and cytokine secretion by native human acute myelogenous leukemia blasts
    Øystein Bruserud
    Division for Hematology, Department of Medicine, Haukeland University Hospital, and The University of Bergen, Bergen, Norway
    Eur J Haematol 71:9-17. 2003
  9. ncbi request reprint Anticancer immunotherapy in combination with proapoptotic therapy
    Øystein Bruserud
    Section for Hematology, Institute for Internal Medicine, University of Bergen, Bergen, Norway
    Curr Cancer Drug Targets 8:666-75. 2008
  10. ncbi request reprint In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22
    Astrid Marta Olsnes
    Department of Medicine, Division for Hematology, Haukeland University Hospital Institute of Medicine and The University of Bergen, Bergen, Norway
    J Interferon Cytokine Res 28:297-310. 2008

Collaborators

Detail Information

Publications126 found, 100 shown here

  1. doi request reprint The chemokine system in experimental and clinical hematology
    Øystein Bruserud
    Section for Hematology, Institute of Internal Medicine, University of Bergen, Bergen, Norway
    Curr Top Microbiol Immunol 341:3-12. 2010
    ....
  2. ncbi request reprint Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies
    Oystein Bruserud
    Section for Hematology, Institute of Clinical Science, University of Bergen, Bergen, Norway
    Cancer Immunol Immunother 63:757-77. 2014
    ....
  3. pmc Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience
    Knut Liseth
    Department of Immunology and Transfusion Medicine, Haukeland University Hospital, Bergen, Norway
    J Biomed Biotechnol 2010:692097. 2010
    ..Such combinatory regimens should be suitable for patients with aggressive hematological malignancies and probably also for other cancer patients...
  4. ncbi request reprint Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML
    Øystein Bruserud
    Division for Hematology, Department of Medicine, Haukeland University Hospital, N 5021 Bergen, Norway
    Expert Opin Ther Targets 10:51-68. 2006
    ..Taken together, these studies suggest that HDAC inhibition can mediate antileukaemic effects in AML, but for most patients the clinical benefit seems limited and further studies of combination therapy are required...
  5. ncbi request reprint In vitro culture of human acute lymphoblastic leukemia (ALL) cells in serum-free media; a comparison of native ALL blasts, ALL cell lines and virus-transformed B cell lines
    Øystein Bruserud
    Medical Department, Division of Hematology, Institute of Medicine, Haukeland University Hospital, N 5021 Bergen, Norway
    Leuk Res 27:455-64. 2003
    ..Our experimental model can thereby be used for in vitro evaluation of possible antileukemic treatment strategies, and it will then allow comparison of experimental results between different studies...
  6. ncbi request reprint Human acute lymphoblastic leukemia (ALL) blasts as accessory cells during T-cell activation: differences between patients in costimulatory capacity affect proliferative responsiveness and cytokine release by activated T cells
    Oystein Bruserud
    Division of Hematology, Department of Medicine, Haukeland University Hospital, N 5021, Bergen, Norway
    Cancer Immunol Immunother 52:215-25. 2003
    ....
  7. ncbi request reprint Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities
    Øystein Bruserud
    Department of Medicine, Haukeland University Hospital, N 5021 Bergen, Norway
    Haematologica 88:416-28. 2003
    ..The aim of this study was to compare functional effects of exogenous Flt3-L on AML blast populations with and without genetic Flt3 abnormalities...
  8. ncbi request reprint Effects of angiogenic regulators on in vitro proliferation and cytokine secretion by native human acute myelogenous leukemia blasts
    Øystein Bruserud
    Division for Hematology, Department of Medicine, Haukeland University Hospital, and The University of Bergen, Bergen, Norway
    Eur J Haematol 71:9-17. 2003
    ....
  9. ncbi request reprint Anticancer immunotherapy in combination with proapoptotic therapy
    Øystein Bruserud
    Section for Hematology, Institute for Internal Medicine, University of Bergen, Bergen, Norway
    Curr Cancer Drug Targets 8:666-75. 2008
    ..All these issues need to be considered in the design of future clinical studies combining chemotherapy and immunotherapy...
  10. ncbi request reprint In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22
    Astrid Marta Olsnes
    Department of Medicine, Division for Hematology, Haukeland University Hospital Institute of Medicine and The University of Bergen, Bergen, Norway
    J Interferon Cytokine Res 28:297-310. 2008
    ..Induction of a dendritic AML cell phenotype is associated with an altered chemokine release profile. Detailed characterization of chemokine release should be included in future studies of AML-DC vaccination...
  11. ncbi request reprint Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts
    Øystein Bruserud
    Division for Hematology, Department of Medicine, Haukeland University Hospital and the University of Bergen, Bergen, Norway
    Haematologica 89:391-402. 2004
    ..Recent studies have focused on the endothelial cells, but other non-leukemic cells may also be involved. In the present study we investigated how osteoblasts affect native human AML blasts...
  12. ncbi request reprint Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell
    Ø Bruserud
    Section for Hematology, The University of Bergen and Haukeland University Hospital, Bergen, Norway
    Curr Pharm Biotechnol 8:388-400. 2007
    ..Even though the initial studies are encouraging, additional in vitro and in vivo pharmacological characterization is definitely needed...
  13. ncbi request reprint Introduction: RNA and the treatment of human cancer
    Oystein Bruserud
    Division of Haematology, Institute of Medicine and Department of Medicine and The Translational Research Program, University of Bergen, Haukeland University Hospital, N 5021 Bergen, Norway
    Curr Pharm Biotechnol 8:318-9. 2007
    ....
  14. ncbi request reprint Lipoteichoic acid derived from Enterococcus faecalis modulates the functional characteristics of both normal peripheral blood leukocytes and native human acute myelogenous leukemia blasts
    Øystein Bruserud
    Division of Hematology, Haukeland University Hospital and the University of Bergen, Bergen, Norway
    Eur J Haematol 73:340-50. 2004
    ..Lipoteichoic acid (LTA) is a cell wall component of gram-positive bacteria, and it can activate normal immunocompetent cells through binding to specific cell membrane receptors...
  15. ncbi request reprint Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia?
    Øystein Bruserud
    Section for Hematology, Institute of Medicine, The University of Bergen, Bergen, Norway
    Cancer Immunol Immunother 55:221-8. 2006
    ..g. heat shock protein 90 inhibitors, proteasome inhibitors, inhibition of angiogenesis) appear to affect T cells only at relatively high concentrations and may thus be used in combination with immunotherapy...
  16. ncbi request reprint In vitro culture of human osteosarcoma cell lines: a comparison of functional characteristics for cell lines cultured in medium without and with fetal calf serum
    Oystein Bruserud
    Section for Hematology, Institute of Medicine, The University of Bergen, Bergen, Norway
    J Cancer Res Clin Oncol 131:377-84. 2005
    ..To improve the standardisation we have investigated whether serum-free culture media can be used in experimental in vitro studies of osteosarcoma cell lines...
  17. ncbi request reprint Immunotherapy in chronic lymphocytic leukemia
    Øystein Bruserud
    Section for Hematology, Institute of Medicine, The University of Bergen, Bergen, Norway
    Cancer Immunol Immunother 55:185-7. 2006
  18. ncbi request reprint Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells
    Øystein Bruserud
    Division for Hematology, Department of Medicine, Haukeland University Hospital and the University of Bergen, Bergen, Norway
    Haematologica 92:332-41. 2007
    ..In the present study we investigated the effects of various chemokines on proliferation of acute myelogenous leukemia (AML) cells and constitutive chemokine release by primary AML cells...
  19. ncbi request reprint Serum levels of angioregulatory mediators in healthy individuals depend on age and physical activity: studies of angiogenin, basic fibroblast growth factor, leptin and endostatin
    O Bruserud
    Division for Haematology, Department of Medicine, Haukeland University Hospital, University of Bergen, Bergen, Norway
    Scand J Clin Lab Invest 65:505-11. 2005
    ..The aim of the present study was to investigate whether physical activity alters systemic levels of angioregulatory mediators in healthy individuals...
  20. ncbi request reprint A critical review of T cell targeting immunotherapy in pancreatic cancer: only a hypothesis or a real hope for the patients?
    Øystein Bruserud
    Department of Internal Medicine, Haukeland University Hospital N 5021 Bergen, Norway
    Expert Opin Biol Ther 2:693-701. 2002
    ..T cell targeting immunotherapy will contribute to the hope of curative treatment in patients with inoperable tumours if such combinatory approaches can be developed...
  21. ncbi request reprint Acute myelogenous leukemia blasts as accessory cells during in vitro T lymphocyte activation
    O Bruserud
    Division for Hematology, Medical Department, Haukeland University Hospital, N 5021 University of Bergen, Bergen, Norway
    Cell Immunol 206:36-50. 2000
    ..Although there is a wide interpatient variation, we conclude that for a majority of patients the native AML blasts can mediate adequate costimulatory signals needed for accessory cell-dependent T cell activation...
  22. ncbi request reprint New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of aml cells--the present use in experimental studies and the possible importance for future therapeutic approaches
    O Bruserud
    Division for Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
    Stem Cells 19:1-11. 2001
    ....
  23. ncbi request reprint Use of marine toxins in combination with cytotoxic drugs for induction of apoptosis in acute myelogenous leukaemia cells
    Øystein Bruserud
    Division for Hematology, Department of Medicine, Haukeland University Hospital, N 5021 Bergen, Norway
    Expert Opin Biol Ther 2:197-210. 2002
    ..Other problems that have to be addressed are the possible effect of the toxins' tumour promoting effects on chemosensitivity in relapsed AML and the possibility of cross-resistance between cytotoxic drugs and toxins...
  24. doi request reprint Therapeutic targeting of NF-κB in myelodysplastic syndromes and acute myeloid leukaemia - the biological heterogeneity
    Øystein Bruserud
    University of Bergen, Institute of Internal Medicine, Bergen, Norway
    Expert Opin Ther Targets 14:1139-42. 2010
    ..g. proteasomal inhibitiors versus specific inhibitors. Even though initial studies suggest that NF-κB inhibitors have antileukemic effects, their future clinical use will also depend on their toxicity profile...
  25. ncbi request reprint Effects of azoles on human acute myelogenous leukemia blasts and T lymphocytes derived from acute leukemia patients with chemotherapy-induced cytopenia
    O Bruserud
    Department of Medicine, Haukeland University Hospital and the University of Bergen, Norway
    Int Immunopharmacol 1:2183-95. 2001
    ....
  26. ncbi request reprint New strategies in the treatment of acute myelogenous leukemia: mobilization and transplantation of autologous peripheral blood stem cells in adult patients
    O Bruserud
    Division for Hematology, Department of Medicine, Haukeland University Hospital and the University of Bergen, Bergen, Norway
    Stem Cells 18:343-51. 2000
    ....
  27. ncbi request reprint Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy?
    Ø Bruserud
    Division of Hematology, Department of Medicine, Haukeland University Hospital and the University of Bergen, Norway
    Expert Opin Biol Ther 1:1005-16. 2001
    ....
  28. ncbi request reprint In vitro culture of human acute myelogenous leukemia (AML) cells in serum-free media: studies of native AML blasts and AML cell lines
    O Bruserud
    Institute of Medicine, Division of Hematology, Medical Department, Haukeland University Hospital, N 5021 Bergen, Norway
    J Hematother Stem Cell Res 9:923-32. 2000
    ..We conclude that standardized serum-free culture conditions can be used for in vitro studies of native AML blasts and AML cell lines...
  29. ncbi request reprint Leptin in human acute myelogenous leukemia: studies of in vivo levels and in vitro effects on native functional leukemia blasts
    Øystein Bruserud
    Medical Department, Haukeland University Hospital, N 5021 Bergen, Norway
    Haematologica 87:584-95. 2002
    ..We investigated systemic leptin levels in AML patients and in vitro effects of leptin on cultured AML blasts...
  30. ncbi request reprint Expression of Fc(epsilon)-receptors by human acute myelogenous leukemia (AML) blasts: studies of high- and low- (CD23) affinity receptor expression and the effects of IgE-mediated receptor ligation on functional AML blast characteristics
    Ø Bruserud
    Division for Hematology, Medical Department, The Gade Institute, Haukeland University Hospital, University of Bergen, N 5021 Bergen, Norway
    Leuk Res 26:515-21. 2002
    ..We conclude that functional Fc(epsilon)R can be expressed by human AML cells...
  31. ncbi request reprint Circadian variations do not have a major impact on serum levels of soluble (S) L-selectin (CD63L), S-intercellular adhesion molecule 1 (sICAM-1/CD54) and thrombopoietin in healthy individuals
    K A Mosevold
    Department of Medicine, University of Bergen and Haukeland University Hospital, Bergen, Norway
    Scand J Clin Lab Invest 62:75-9. 2002
    ..The results suggest that serum sampling at standardized times is probably not required in the future clinical evaluation of these three parameters...
  32. doi request reprint Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation
    Hakon Reikvam
    Institute of Internal Medicine, Division for Hematology, University of Bergen, Bergen, Norway
    Eur J Haematol 84:239-51. 2010
    ..We investigated the constitutive release of MMPs and TIMPs for a large group of consecutive AML patients...
  33. ncbi request reprint Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention
    Hakon Reikvam
    Division for Haematology, Institute of Medicine, University of Bergen, Norway
    Br J Haematol 156:468-80. 2012
    ..Finally, HSP90 inhibition counteracted the leukaemia-stimulating effect of endothelial cells. Our studies demonstrate that HSP90 inhibition mediates anti-leukaemic effects through both direct and indirect activity...
  34. ncbi request reprint In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8
    Anita Ryningen
    Division for Hematology, Department of Medicine, Haukeland University Hospital, N 5021 Bergen, Norway
    Leuk Res 29:185-96. 2005
    ..This bidirectional crosstalk via the cytokine network between AML blasts and fibroblasts caused (i) increased proliferation, (ii) mediated antiapoptotic signalling and (iii) increased local levels of proangiogenic IL8...
  35. ncbi request reprint The angioregulatory phenotype of native human acute myelogenous leukemia cells: influence of karyotype, Flt3 abnormalities and differentiation status
    Nils Glenjen
    Section for Hematology, Department of Medicine, Haukeland University Hospital and the University of Bergen, Bergen, Norway
    Eur J Haematol 71:163-73. 2003
    ..The aim of the study was to investigate possible associations between genetic abnormalities, differentiation status and angioregulatory phenotype in native human AML blasts...
  36. ncbi request reprint The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells
    Camilla Stapnes
    Institute of Medicine, University of Bergen, Bergen, Norway
    Br J Haematol 136:814-28. 2007
    ..We conclude that nanomolar levels of the proteasome inhibitors tested had dose-dependent antiproliferative and proapoptotic effects on primary AML cells in vitro...
  37. ncbi request reprint Effects of interferon gamma on native human acute myelogenous leukaemia cells
    Elisabeth Ersvaer
    Institute of Medicine, Section for Hematology, The University of Bergen and Haukeland University Hospital, Bergen, Norway
    Cancer Immunol Immunother 56:13-24. 2007
    ..We conclude that IFNgamma can be released in the presence of native human AML cells and affect AML cell proliferation, regulation of apoptosis and the balance between pro- and antiangiogenic chemokine release...
  38. ncbi request reprint T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC)
    Astrid Marta Olsnes
    Division for Hematology, Department of Medicine, Haukeland University Hospital and the University of Bergen, Bergen, Norway
    Cancer Immunol Immunother 55:830-40. 2006
    ....
  39. doi request reprint High-dose etoposide in allogeneic stem cell transplantation
    Oystein Bruserud
    Department of Medicine, Section of Hematology, Haukeland University Hospital, Bergen, Norway
    Cancer Chemother Pharmacol 70:765-82. 2012
    ....
  40. doi request reprint Hematopoietic engraftment of dimethyl sulfoxide-depleted autologous peripheral blood progenitor cells
    Ciğdem A Akkök
    Department of Immunology and Transfusion Medicine, the Centre of Clinical Research, Ullevaal University Hospital, Oslo, Norway
    Transfusion 49:354-61. 2009
    ..The aim was to investigate whether DMSO depletion by manual single wash reduced frequency of adverse effects or had detrimental effects on the engraftment potential of peripheral blood progenitor cell (PBPC) autografts...
  41. ncbi request reprint Global gene expression in classification, pathogenetic understanding and identification of therapeutic targets in acute myeloid leukemia
    Anne Margrete Oyan
    Department of Microbiology and Immunology, Haukeland University Hospital, University of Bergen, Bergen, Norway
    Curr Pharm Biotechnol 8:344-54. 2007
    ..The present review weighs up the results and their potentialities with reference to gene expression analysis in acute myeloid leukemia (AML)...
  42. doi request reprint Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment
    Hanne Fredly
    Section for Hematology, Institute of Medicine, University of Bergen, Bergen, Norway
    Am J Hematol 87:368-76. 2012
    ..We conclude that both HSP levels and serum cytokine profiles are altered and may represent possible therapeutic targets or prognostic markers in human AML...
  43. ncbi request reprint Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients
    Elisabeth Ersvaer
    Institute of Medicine, University of Bergen, Bergen, Norway
    Eur J Haematol 79:210-25. 2007
    ..We therefore investigated (i) whether a similar expression pattern could be detected in native human acute myelogenous leukemia (AML) cells and (ii) whether cyclin B1 specific antibodies could be detected in AML...
  44. ncbi request reprint In vivo biological effects of ATRA in the treatment of AML
    Anita Ryningen
    University of Bergen, Haukeland University Hospital and Institute of Medicine, Division of Hematology, Department of Medicine, Bergen
    Expert Opin Investig Drugs 17:1623-33. 2008
    ..Experimental studies suggest that ATRA can induce differentiation and apoptosis in leukaemia cells also for other acute myelogenous leukaemia (AML) subtypes, but the clinical observations are conflicting...
  45. ncbi request reprint Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting
    Anita Ryningen
    Division for Hematology, Department of Medicine, Haukeland University Hospital and University of Bergen, N 5021 Bergen, Norway
    Leuk Res 31:1303-13. 2007
    ....
  46. ncbi request reprint A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia
    Nina Anensen
    Hematology Section, Institute of Medicine, University of Bergen, Norway
    Clin Cancer Res 12:3985-92. 2006
    ..This study examined the early p53 protein and gene expression during induction chemotherapy in acute myeloid leukemia (AML)...
  47. ncbi request reprint Autologous peripheral blood progenitor cells cryopreserved with 5 and 10 percent dimethyl sulfoxide alone give comparable hematopoietic reconstitution after transplantation
    Ciğdem A Akkök
    Blood Bank, The Division of Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
    Transfusion 48:877-83. 2008
    ....
  48. doi request reprint Therapeutic efficacy of platelet transfusion in patients with acute leukemia: an evaluation of methods
    Torunn O Apelseth
    Blood Bank, the Section for Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
    Transfusion 50:766-75. 2010
    ..In this study we evaluate and compare transfusion effect measures in patients with chemotherapy-induced thrombocytopenia due to treatment of acute leukemia...
  49. doi request reprint Effects of peripheral blood stem cell apheresis on systemic cytokine levels in patients with multiple myeloma
    Ciğdem Akalin Akkök
    Department of Immunology and Transfusion Medicine, Haukeland University Hospital, Bergen, Norway
    Cytotherapy 13:1259-68. 2011
    ..Our results show that PBSC apheresis alters systemic angioregulatory profiles in myeloma patients. This cytokine modulation is not a general characteristic of all apheresis procedures and was not seen in healthy platelet donors...
  50. ncbi request reprint Circulating T cells derived from acute leukemia patients with severe therapy-induced cytopenia express a wide range of chemokine receptors
    Astrid Marta Olsnes
    Division for Hematology, Department of Medicine, Haukeland University Hospital and the University of Bergen, Bergen, Norway
    Hematology 13:329-32. 2008
    ....
  51. ncbi request reprint Hypoxia increases HIF-1α expression and constitutive cytokine release by primary human acute myeloid leukaemia cells
    Kimberley Joanne Hatfield
    Department of Medicine, Division of Haematology, Haukeland University Hospital, Bergen, Norway
    Eur Cytokine Netw 21:154-64. 2010
    ..Angiogenesis has been shown to play a role in haematological disorders, and low oxygen tension might thereby influence leukaemogenesis and chemosensitivity in human acute myeloid leukaemia (AML)...
  52. ncbi request reprint In vitro effects of native human acute myelogenous leukemia blasts on fibroblasts and osteoblasts
    Nils Glenjen
    Section for Hematology, Department of Medicine, Haukeland University Hospital and University of Bergen, Bergen, Norway
    Int J Cancer 111:858-67. 2004
    ....
  53. ncbi request reprint Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release
    Hakon Reikvam
    University of Bergen, Institute of Internal Medicine, Division of Haematology, Bergen, Norway
    Expert Opin Investig Drugs 19:169-83. 2010
    ..Tie-2 can be expressed both by primary human acute myeloid leukaemia (AML) cells and endothelial cells, and Tie-2-blocking antibodies are now being evaluated in clinical trials for cancer treatment...
  54. ncbi request reprint Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization
    Kjell Petersen
    Computational Biology Unit, Bergen Center for Computational Science, University of Bergen, N 5008 Bergen, Norway
    Anal Biochem 366:46-58. 2007
    ..Therefore, structurally exceptional RNA species can be identified by comparing targets derived from either poly(A) RNA or total RNA using microarray hybridization...
  55. ncbi request reprint Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia
    Øystein Wendelbo
    Division for Infectious Diseases, Department of Medicine, Haukeland University Hospital, University of Bergen, Norway
    Cancer Immunol Immunother 53:740-7. 2004
    ....
  56. ncbi request reprint Effects of vascular endothelial growth factor on acute myelogenous leukemia blasts
    B Foss
    Institute of Medicine, The University of Bergen and Haukeland University Hospital, N-5021 Bergen, Norway
    J Hematother Stem Cell Res 10:81-93. 2001
    ..Our results suggest that VEGF is important in leukemic hematopoiesis, and the detection of VEGF in PBSC autografts indicates that VEGF may influence the functional phenotype of contaminating AML cells in these grafts...
  57. pmc The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine—the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation
    Hakon Reikvam
    Section for Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
    Toxins (Basel) 5:336-62. 2013
    ....
  58. doi request reprint The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation
    Hakon Reikvam
    Section for Hematology, Department of Medicine, Haukeland University Hospital and Institute of Medicine, University of Bergen
    Eur Cytokine Netw 23:140-53. 2012
    ..We shall also discuss the possibility of targeting angioregulatory cytokines as a part of the treatment strategy in leukemia...
  59. doi request reprint Future perspectives: should Th17 cells be considered as a possible therapeutic target in acute myeloid leukemia patients receiving allogeneic stem cell transplantation?
    Elisabeth Ersvær
    Division for Hematology, Institute of Internal Medicine, University of Bergen, Norway
    Cancer Immunol Immunother 60:1669-81. 2011
    ..In the present article, we review previous studies of Th17 cells in AML and in the development of GVHD, possible therapeutic strategies and available therapeutic tools for targeting of Th17 cells...
  60. doi request reprint A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid
    Anita Ryningen
    Institute of Internal Medicine, University of Bergen, Bergen, Norway
    Leuk Res 33:779-87. 2009
    ..We conclude that the therapy causes disease stabilization for a subset of AML patients...
  61. doi request reprint Current practice and future directions for optimization of platelet transfusions in patients with severe therapy-induced cytopenia
    Torunn O Apelseth
    Department of Immunology and Transfusion Medicine, Haukeland University Hospital, Norway
    Blood Rev 25:113-22. 2011
    ..Thus, several questions with regard to the optimal use of platelet transfusions in cancer patients still need to be answered...
  62. ncbi request reprint CD34 expression in native human acute myelogenous leukemia blasts: differences in CD34 membrane molecule expression are associated with different gene expression profiles
    Anne Margrete Oyan
    Department of Microbiology and Immunology, Haukeland University Hospital, Bergen, Norway
    Cytometry B Clin Cytom 64:18-27. 2005
    ..The present study investigated whether gene expression profiling could be used to further subclassify CD34(+) AML cell populations...
  63. ncbi request reprint Acute myelogenous leukemia with internal tandem duplication of the Flt3 gene appearing or altering at the time of relapse: a report of two cases
    Randi Hovland
    Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital and University of Bergen, Bergen, Norway
    Leuk Lymphoma 43:2027-9. 2002
    ....
  64. ncbi request reprint Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts
    Kimberley Hatfield
    Section for Hematology, Institute of Medicine, The University of Bergen, Bergen, Norway
    Int J Cancer 119:2313-21. 2006
    ....
  65. ncbi request reprint Use of different DMSO concentrations for cryopreservation of autologous peripheral blood stem cell grafts does not have any major impact on levels of leukocyte- and platelet-derived soluble mediators
    Ciğdem Akalin Akkök
    Division of Hematology, Department of Medicine, Haukeland University Hospital and Institute of Medicine, University of Bergen, Bergen, Norway
    Cytotherapy 11:749-60. 2009
    ....
  66. ncbi request reprint The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells
    Astrid Marta Olsnes
    Division for Haematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
    Br J Haematol 145:761-74. 2009
    ..Previous studies have described proapoptotic and T cell stimulatory effects and the present study describes additional T cell chemotactic and differentiation-inducing effects...
  67. ncbi request reprint Epigenetic targeting in acute myeloid leukemia: use of flow cytometry in monitoring therapeutic effects
    Anita Ryningen
    Section for Hematology, Haukeland University Hospital, Bergen, Norway
    Curr Pharm Biotechnol 8:401-11. 2007
    ....
  68. ncbi request reprint T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005
    Elisabeth Ersvaer
    Section for Hematology, Institute of Medicine, The University of Bergen and Haukeland University Hospital, 5021 Bergen, Norway
    Cancer Immunol Immunother 56:913-25. 2007
    ....
  69. pmc Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia
    Anne Margrete Øyan
    Institute of Medicine, Hematology Section, University of Bergen, Bergen, Norway
    BMC Cancer 9:77. 2009
    ..The molecular changes in vivo in acute myeloid leukemia cells early after start of conventional genotoxic chemotherapy are incompletely understood, and it is not known if early molecular modulations reflect clinical response...
  70. doi request reprint Stem cell mobilization and harvesting by leukapheresis alters systemic cytokine levels in patients with multiple myeloma
    Knut Anders Mosevoll
    Department of Medicine, Haukeland University Hospital, Bergen, Norway
    Cytotherapy 15:850-60. 2013
    ..In the present study, we investigated the effects of these interventions on a larger group of cytokines...
  71. doi request reprint Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors
    Hakon Reikvam
    University of Bergen, Department of Clinical Science, Division for Hematology, Bergen, Norway
    Expert Opin Investig Drugs 22:551-63. 2013
    ..HSP90, and more recently HSP70, have emerged as possible therapeutic targets in human malignancies, including acute myeloid leukemia (AML)...
  72. doi request reprint Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis
    Hanne Fredly
    Section for Hematology, Institute of Internal Medicine, University of Bergen, Bergen, Norway
    Oncol Rep 25:1549-56. 2011
    ....
  73. doi request reprint The chemokine system in allogeneic stem-cell transplantation: a possible therapeutic target?
    Guro Kristin Melve
    Department of Immunology and Transfusion Medicine, Haukeland University Hospital, Bergen, Norway
    Expert Rev Hematol 4:563-76. 2011
    ..Future clinical studies should therefore be based on a better characterization of various immunocompetent cells, including their chemokine receptor profile, both in the allografts and during post-transplant reconstitution...
  74. ncbi request reprint Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions?
    Hakon Reikvam
    Section of Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
    Curr Cancer Drug Targets 13:30-47. 2013
    ..The designs of future clinical trials have to carefully consider the antileukemic and immunomodulatory effects together with the risk of especially hematological toxicity...
  75. ncbi request reprint Cryopreserving human peripheral blood progenitor cells with 5-percent rather than 10-percent DMSO results in less apoptosis and necrosis in CD34+ cells
    Jenny Foss Abrahamsen
    Blood Bank, Haukeland University Hospital, Bergen, Norway
    Transfusion 42:1573-80. 2002
    ..This study was initiated to investigate whether cell viability, apoptosis, and necrosis would be altered in CD34+ cells if PBPCs were cryopreserved with 5-percent as opposed to the conventional 10-percent DMSO...
  76. doi request reprint Long-term cryopreservation of autologous stem cell grafts: a clinical and experimental study of hematopoietic and immunocompetent cells
    Knut Liseth
    The Blood Bank, Haukeland University Hospital, Jonas Liesvei 65, N 5021 Bergen, Norway
    Transfusion 49:1709-19. 2009
    ..Harvesting sufficient peripheral blood progenitor cells (PBPCs) for a potential second autotransplantation at the time of relapse several years after diagnosis is becoming an increasingly common practice...
  77. ncbi request reprint Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia
    Nils Glenjen
    Section for Hematology, Department of Medicine, Haukeland University Hospital and the University of Bergen, Norway
    Int J Cancer 101:86-94. 2002
    ..Our results suggest that intensive chemotherapy can modulate the systemic component of angiogenic regulation in AML patients...
  78. ncbi request reprint Interleukin-7 (IL-7) in patients receiving intensive chemotherapy for acute myelogenous leukemia: studies of systemic IL-7 Levels and IL-7 responsiveness of circulating T lymphocytes
    Øystein Wendelbo
    Section for Hematology, Department of Medicine, Haukeland University Hospital and the University of Bergen, Bergen, Norway
    J Interferon Cytokine Res 22:1057-65. 2002
    ....
  79. ncbi request reprint Functional evaluation of proliferative T cell responses in patients with severe T lymphopenia: characterization of optimal culture conditions and standardized activation signals for a simple whole blood assay
    Øystein Wendelbo
    Division for Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
    J Hematother Stem Cell Res 12:525-35. 2003
    ..Detectable proliferation is observed for most patients with treatment-induced cytopenia. We conclude that the assay can be used for functional characterization of remaining T lymphocytes in patients with severe T lymphopenia...
  80. pmc Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells
    Elisabeth Ersvaer
    Institute of Medicine, University of Bergen, Bergen, Norway
    BMC Immunol 11:38. 2010
    ..We therefore investigated the frequencies of various T cell subsets (TC1, TH1, TH17) and CD25+ FoxP3+ TREG cells in AML patients with untreated disease and following intensive chemotherapy...
  81. ncbi request reprint Cellular immune responses in multiple myeloma patients with treatment-induced cytopenia early after high-dose chemotherapy and autologous peripheral blood stem cell transplantation
    Øystein Wendelbo
    Department of Medicine, Haukeland University Hospital, N 5021 Bergen, Norway
    Leuk Res 28:461-8. 2004
    ..Our results suggest that myeloma patients with post-transplant cytopenia have a more severe cellular immune defect than patients with other hematological malignancies and severe cytopenia due to conventional intensive chemotherapy...
  82. ncbi request reprint Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and 90
    Anita Ryningen
    Division for Hematology, Department of Medicine, Haukeland University Hospital and the University of Bergen, Bergen, Norway
    Leuk Res 30:1531-40. 2006
    ....
  83. ncbi request reprint Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors
    Camilla Stapnes
    Institute of Medicine, University of Bergen Haukeland University Hospital, N 5021, Bergen, Norway
    Int J Oncol 31:1529-38. 2007
    ..Functional characterization and gene expression analyses identify AML patient subsets that differ in their response to HDAC inhibitors. These observations may explain why HDAC inhibitor therapy affects only a subset of patients...
  84. ncbi request reprint In vitro effects of insulin-like growth factor-1 (IGF-1) on proliferation and constitutive cytokine secretion by acute myelogenous leukemia blasts
    S Frostad
    Medical Department B, Haukeland University Hospital, Norway
    Eur J Haematol 62:191-8. 1999
    ..Our in vitro observations indicate that IGF-1 can modulate AML blast proliferation and/or cytokine secretion for a subset of patients...
  85. ncbi request reprint Coculture of native human acute myelogenous leukemia blasts with fibroblasts and osteoblasts results in an increase of vascular endothelial growth factor levels
    Nils Idar Glenjen
    Division for Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
    Eur J Haematol 74:24-34. 2005
    ..Proangiogenic vascular endothelial growth factor (VEGF) is constitutively secreted by the AML blasts for a subset of patients, but it can also be released by non-leukemic bone marrow cells...
  86. pmc Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia
    Ingvild Haaland
    Department of Internal Medicine, Haukeland University Hospital, Bergen N 5021, Norway
    Mol Cancer 13:116. 2014
    ....
  87. doi request reprint Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect
    Hakon Reikvam
    Department of Clinical Science, University of Bergen, Bergen, Norway Division of Haematology, Department of Medicine, Haukeland University, Bergen, Norway
    Br J Haematol 164:200-11. 2014
    ....
  88. pmc Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells
    Hakon Reikvam
    Section for Hematology, Department of Clinical Science, University of Bergen, Norway
    Oncotarget 4:830-43. 2013
    ..PI3K and mTOR inhibitors can decrease constitutive cytokine release both by AML and stromal cells, suggesting potential direct and indirect antileukemic effects. ..
  89. doi request reprint Soluble mediators released by acute myeloid leukemia cells increase capillary-like networks
    Kimberley J Hatfield
    Section for Hematology, Department of Medicine, Haukeland University Hospital, and Department of Hematology, University of Bergen, Bergen, Norway
    Eur J Haematol 89:478-90. 2012
    ..Our study shows that AML-derived cytokines can induce the organization of endothelial cells into vessel-like structures...
  90. pmc Future perspectives: therapeutic targeting of notch signalling may become a strategy in patients receiving stem cell transplantation for hematologic malignancies
    Elisabeth Ersvaer
    Division of Hematology, Department of Medicine, Haukeland University Hospital and Institute of Medicine, University of Bergen, N 5021 Bergen, Norway
    Bone Marrow Res 2011:570796. 2011
    ....
  91. pmc The protein kinase C agonist PEP005 (ingenol 3-angelate) in the treatment of human cancer: a balance between efficacy and toxicity
    Elisabeth Ersvaer
    Section for Hematology, The University of Bergen, Bergen, Norway
    Toxins (Basel) 2:174-94. 2010
    ....
  92. ncbi request reprint Nuclear Factor-kappaB Signaling: A Contributor in Leukemogenesis and a Target for Pharmacological Intervention in Human Acute Myelogenous Leukemia
    Hakon Reikvam
    Division for Hematology, Institute of Medicine, University of Bergen, Bergen, Norway
    Crit Rev Oncog 15:1-36. 2009
    ..The clinical documentation with regard to the effciency and safety of NF-kappaB inhibition is still limited, but experimental evidence strongly suggests that NF-kappaB inhibition should be further investigated in human AML...
  93. ncbi request reprint Better preservation of early hematopoietic progenitor cells when human peripheral blood progenitor cells are cryopreserved with 5 percent dimethylsulfoxide instead of 10 percent dimethylsulfoxide
    Jenny Foss Abrahamsen
    Blood Bank, Haukeland University Hospital, Bergen, Norway
    Transfusion 44:785-9. 2004
    ....
  94. ncbi request reprint Modified fatty acids and their possible therapeutic targets in malignant diseases
    Karl J Tronstad
    Institute of Medicine, Section of Medical Biochemistry, University of Bergen, Haukeland University Hospital, N 5021 Bergen, Norway
    Expert Opin Ther Targets 7:663-77. 2003
    ....
  95. doi request reprint Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators
    Kimberley Hatfield
    Section for Haematology, Institute of Medicine, University of Bergen, Norway
    Br J Haematol 144:53-68. 2009
    ..Our study indicates a role for the leukaemic-endothelium crosstalk in leukaemogenesis with enhancement of endothelial cell growth and increased AML cell proliferation possibly mediated by angiopoietin-1 and the STAT signalling pathway...
  96. ncbi request reprint Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex
    Elisabeth Ersvaer
    University of Bergen and Haukeland University Hospital, Institute of Medicine, Bergen, Norway
    Hematology 12:199-207. 2007
    ..For a subset of patients T cell responsiveness can be further increased by targeting PKC and these data therefore suggest that T cell function is not inhibited in AML patients...
  97. ncbi request reprint How should clinical data be included in experimental studies of cancer immunology?
    Bjørn Tore Gjertsen
    University of Bergen, Norway
    Cancer Immunol Immunother 53:677-80. 2004
    ..Guidelines for selection of relevant information are suggested in the article...
  98. ncbi request reprint Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia
    Emmet McCormack
    Institute of Medicine, Hematology Section, University of Bergen, Bergen, Norway
    Blood 121:e34-42. 2013
    ..We present herein an optimizedapplication of multiplexed immunolabeling in vivo for optical imaging of AML cellxenografts that provides reproducible, highly accurate disease staging and monitoring of therapeutic effects...
  99. pmc Inhibition of Mammalian target of rapamycin in human acute myeloid leukemia cells has diverse effects that depend on the environmental in vitro stress
    Anita Ryningen
    Division of Hematology, Institute of Medicine, University of Bergen, N 5021 Bergen, Norway Department of Medicine, Haukeland University Hospital, N 5021 Bergen, Norway
    Bone Marrow Res 2012:329061. 2012
    ....
  100. ncbi request reprint Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?
    Galina Tsykunova
    Haukeland University Hospital, Division for Haematology, Department of Medicine, Bergen, Norway
    Expert Opin Investig Drugs 21:587-603. 2012
    ..Five human polo-like kinases (PLKs) have been identified, and PLK1 - 4 seem to interact with Aurora kinases and act as cell cycle regulators in both normal and malignant human cells...
  101. doi request reprint Serum levels of endothelium-derived endocan are increased in patients with untreated acute myeloid leukemia
    Kimberley Joanne Hatfield
    Section for Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
    Hematology 16:351-6. 2011
    ..To conclude, serum endocan is a disease marker in AML, but serum levels are also affected by complicating infections and bone marrow regeneration...